Recently diagnosed with HIV? Click here

SPARTAC (early intervention)

Clinical trial • Fully enrolled • 11 May 2007
This trial is fully enrolled. This means that all of the available places on the trial have been filled. You cannot enrol in this trial.

About this trial

SPARTAC stands for Short Pulse AntiRetroviralA medication or other substance which is active against retroviruses such as HIV. Therapy At seroConversion and the trial compares two different durations of treatment for people who have been very recently infected with HIV. These are compared to a third group of recent seroconverters who remain off treatment altogether.

The trial will compare how each approach affects the immune system. If the immune system can be protected from HIV by treating it for a short period soon after becoming infected, it may be possible to delay the need for ongoing long-term treatment.

It is hoped this approach could reduce life-long exposure to antiretroviral drugs while maintaining clinicalPertaining to or founded on observation and treatment of participants, as distinguished from theoretical or basic science. and immunological well-being.

Official title:A Multi-centre Randomised Trial of Therapeutic Intervention at Primary HIV-1 Infection
What is this trial studying?Treatment strategy
Start date:Feb 2005

This may be the proposed or expected start date for trials which have not yet started.

How many participants will this trial enrol?20

The exact number of participants may be lower or slightly higher than this. Some trials also have specific quotas for participants from each state, city or clinic.

Links to further information:
Tags:newly diagnosed, starting treatments

Who can enrol in this trial?

You may be eligible to participate in this trial if you meet the following criteria:

  • At least 18 years old
  • Recently been infected with HIV, or undergoing seroconversion
  • Newly infected with HIV (last 6 months)
  • Have not yet developed antibodies to HIV
  • Evidence of recent seroconversion illness

This is a summary of key inclusion and exclusion criteria for this trial. There may be other criteria which may exclude some people from participation in this trial. Some laboratory tests may also be required. Consult your doctor, or view the trial protocol or informed consent documentation to see the full range of exclusion and inclusion criteria.

Disclaimer

While NAPWA has taken every care to compile the information on this page and to keep it up-to-date, we cannot guarantee its correctness and completeness.

  • Before making the decision to participate in any clinical research, read our background information.
  • Email NAPWA if you have any questions or comments about this trial
Text size: font smallerfont normalfont larger print-friendly version of this pagePDF version of this pageemail this page to a friend

This Clinical trial was first published on 11 May 2007 — more than four years ago.

While the content of this clinical trial was checked for accuracy at the time of publication, NAPWA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.

This article may contain medical information. NAPWA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.

The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.

Website links

HIV Clinical Trials update

Recently updated entries from the NAPWA Clinical Trials database.

more